Skip to main navigation
Rhythm Pharmaceuticals, Inc. Logo
  • Careers
  • Investors & Media
  • International
  • Search
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Careers
  • Investors & Media
  • International
  • Search
  • Overview
  • Events & Presentations
  • Stock
  • Corporate Governance
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • News
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

News
January 6, 2020
Rhythm Pharmaceuticals Announces Leadership Transition
December 5, 2019
Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
November 13, 2019
Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference
November 4, 2019
Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019
November 1, 2019
Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results
October 30, 2019
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019
October 18, 2019
Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 15, 2019
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
October 15, 2019
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
September 25, 2019
Rhythm Pharmaceuticals Provides Update on Research and Development Programs
  • First page «
  • Previous page ‹
  • …
  • Page 23
  • Page 24
  • Current page 25
  • Page 26
  • Page 27
  • …
  • Next page ›
  • Last page »
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • California Compliance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

This website is intended only for residents of the United States.

© 2026, Rhythm Pharmaceuticals, Inc. All Rights Reserved. Rhythm, IMCIVREE, GOLD Academy, LEAD for Rare Obesity, Uncovering Rare Obesity, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

US-RHY-2400016 05/2024